Eduardo Vieira Ponte1, Álvaro A Cruz2, Valmar Bião Lima2, Rafael Stelmach3, Giovanni Viegi4. 1. Faculdade de Medicina de Jundiaí, R. Francisco Teles, 250, Jundiaí, SP, 13202-550, Brazil. evponte@yahoo.com.br. 2. Núcleo de Excelência em Asma, Salvador, Brazil. 3. Instituto do Coração, São Paulo, Brazil. 4. National Research Council, Rome, Italy.
Abstract
PURPOSE: Long Acting Beta2 Agonists (LABA) prevent COPD exacerbations in strictly standardized clinical trials. Our aim was to evaluate the relationship between the amount of LABA provided by the government and the trend in COPD hospital admission (HA) rate in Brazil. METHODS: This is a longitudinal large-scale real-life study. We calculated COPD HA rate and the number of subjects per 105 inhabitant who received LABA supplied by the government in each Brazilian municipality, between years 2004 and 2013. We used Poisson Multilevel Regression analysis to calculate the rate ratio between LABA dispensation rate and COPD HA rate. RESULTS: In Brazil, COPD HA rate reduced 59% among subjects between 40 and 59 years of age and 60% among subjects older than 59 years of age. Most of the 5506 Brazilian municipalities reduced COPD HA rate [4149 (75%) municipalities & 1357 (25%) municipalities]. The dispensation of LABA was greater among municipalities that reduced COPD HA rate. In the 40-59 age group, the gap in LABA dispensation between the two groups of municipalities increased during the study period from 90.40 to 614.28 subjects per 105 inhabitants. In the > 59 age group, the gap in LABA dispensation increased from 35.87 to 912.99 subjects per 105 inhabitants. For each one hundred subjects who received LABA there was less one HA (RR 0.99, 95 CI 0.99-0.99). CONCLUSIONS: COPD HA rate reduced in Brazil. LABA dispensation growth was associated with COPD HA rate reduction.
PURPOSE: Long Acting Beta2 Agonists (LABA) prevent COPD exacerbations in strictly standardized clinical trials. Our aim was to evaluate the relationship between the amount of LABA provided by the government and the trend in COPD hospital admission (HA) rate in Brazil. METHODS: This is a longitudinal large-scale real-life study. We calculated COPD HA rate and the number of subjects per 105 inhabitant who received LABA supplied by the government in each Brazilian municipality, between years 2004 and 2013. We used Poisson Multilevel Regression analysis to calculate the rate ratio between LABA dispensation rate and COPD HA rate. RESULTS: In Brazil, COPD HA rate reduced 59% among subjects between 40 and 59 years of age and 60% among subjects older than 59 years of age. Most of the 5506 Brazilian municipalities reduced COPD HA rate [4149 (75%) municipalities & 1357 (25%) municipalities]. The dispensation of LABA was greater among municipalities that reduced COPD HA rate. In the 40-59 age group, the gap in LABA dispensation between the two groups of municipalities increased during the study period from 90.40 to 614.28 subjects per 105 inhabitants. In the > 59 age group, the gap in LABA dispensation increased from 35.87 to 912.99 subjects per 105 inhabitants. For each one hundred subjects who received LABA there was less one HA (RR 0.99, 95 CI 0.99-0.99). CONCLUSIONS: COPD HA rate reduced in Brazil. LABA dispensation growth was associated with COPD HA rate reduction.
Entities:
Keywords:
COPD; Epidemiology; Hospitalization; Public health; Treatment
Authors: Joana Mascarenhas; Helena Falcão; Patrícia Lourenço; Cristiana Paulo; Marta Patacho; Paulo Bettencourt; Ana Azevedo Journal: Respir Care Date: 2011-01-27 Impact factor: 2.258
Authors: S Boutin-Forzano; D Moreau; S Kalaboka; E Gay; X Bonnefoy; L Carrozzi; G Viegi; D Charpin; I Annesi-Maesano Journal: Int J Tuberc Lung Dis Date: 2007-06 Impact factor: 2.373
Authors: Michael E Green; Nandini Natajaran; Denis E O'Donnell; Tyler Williamson; Jyoti Kotecha; Shahriar Khan; Andrew Cave Journal: CMAJ Open Date: 2015-01-13
Authors: S Rennard; M Decramer; P M A Calverley; N B Pride; J B Soriano; P A Vermeire; J Vestbo Journal: Eur Respir J Date: 2002-10 Impact factor: 16.671
Authors: Frederik van Gemert; Bruce Kirenga; Niels Chavannes; Moses Kamya; Simon Luzige; Patrick Musinguzi; John Turyagaruka; Rupert Jones; Ioanna Tsiligianni; Sian Williams; Corina de Jong; Thys van der Molen Journal: Lancet Glob Health Date: 2015-01 Impact factor: 26.763
Authors: Max Oscar Bachmann; Eric D Bateman; Rafael Stelmach; Alvaro A Cruz; Matheus Pacheco de Andrade; Ronaldo Zonta; Jorge Zepeda; Sonia Natal; Ruth Vania Cornick; Camilla Wattrus; Lauren Anderson; Daniella Georgeu-Pepper; Carl Lombard; Lara R Fairall Journal: BMJ Glob Health Date: 2019-12-16